These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24133369)

  • 21. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
    Yoshimura N; Okishio K; Mitsuoka S; Kimura T; Kawaguchi T; Kobayashi M; Hirashima T; Daga H; Takeda K; Hirata K; Kudoh S
    J Thorac Oncol; 2013 Jan; 8(1):96-101. PubMed ID: 23207920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
    Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
    Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
    Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
    Goldberg SB; Oxnard GR; Digumarthy S; Muzikansky A; Jackman DM; Lennes IT; Sequist LV
    Oncologist; 2013; 18(11):1214-20. PubMed ID: 24072220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
    Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    Sárosi V; Balikó Z
    Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
    Jänne PA; Wang X; Socinski MA; Crawford J; Stinchcombe TE; Gu L; Capelletti M; Edelman MJ; Villalona-Calero MA; Kratzke R; Vokes EE; Miller VA
    J Clin Oncol; 2012 Jun; 30(17):2063-9. PubMed ID: 22547605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma.
    He Q; Wang Y; Zou P; Wang Y; Xiu C; Zhang H; Chi N; Zou H; Xu J; Zhou S; Tao R
    World Neurosurg; 2017 Mar; 99():758-762. PubMed ID: 27060518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
    Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
    Lee DH; Lee JS; Kim SW; Rodrigues-Pereira J; Han B; Song XQ; Wang J; Kim HK; Sahoo TP; Digumarti R; Wang X; Altug S; Orlando M
    Eur J Cancer; 2013 Oct; 49(15):3111-21. PubMed ID: 23890768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
    Shi SB; Hu RH; Qi JL; Tang XY; Tian J; Li R; Chang CX
    Med Oncol; 2013; 30(2):550. PubMed ID: 23576138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.